EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Therapeutic progress in relapsed/refractory multiple myeloma

Qi Chen, Min Zhang, Shan Zheng, Yuxin Tong, Yamin Tan

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-05730-y ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Annals of Hematology, 2024. Verfasst von Qi Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China. Hauptthemen laut MEDLINE: Multiple Myeloma. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: Natural Science Foundation of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Improvement in the therapeutics for multiple myeloma (MM) has been continuously developed owing to the application of novel drugs and technologies in the last 20 years. The standard first-line therapy for MM consists of a three-drug induction regimen based on immunomodulatory drugs and proteasome inhibitors combined with autologous stem cell transplantation. However, MM remains incurable; therefore, therapies for relapsed/refractory MM (RRMM) are emerging and evolving rapidly. This study aimed to summarize and review the results of RRMM trials over the past 5 years to provide a holistic overview and insights for practitioners in related fields and to provide additional ideas for clinical trialists. This study shows that daratumumab and isatuximab continue to significantly advance as treatment options. Additionally, novel antibody drugs, such as elotuzumab and selinexor, as well as bispecific antibodies, teclistamab and talquetamab, are currently undergoing clinical research with promising outcomes. However, chimeric antigen receptor-T cell therapy targeting B-cell maturation antigen remains the optimal approach for MM treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaHumansAntibodies, Monoclonal, HumanizedAntibodies, MonoclonalImmunotherapy, AdoptiveRecurrenceAntineoplastic Combined Chemotherapy ProtocolsTransplantation, AutologousClinical Trials as TopicAntibodies, BispecificHematopoietic Stem Cell Transplantation

Stichwörter der Autor:innen

Multiple myelomaRefractoryRelapseTherapy

Substanzen

Antibodies, Monoclonal, HumanizeddaratumumabisatuximabAntibodies, MonoclonalelotuzumabAntibodies, Bispecific

Autor:innen und Institutionen

  • Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
  • Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.
  • Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China. yamintan2023@163.com.
  • Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China. yamintan2023@163.com.

Förderung

  • Natural Science Foundation of Zhejiang Province

Zitieren

APA

Chen, Q., Zhang, M., Zheng, S., Tong, Y., & Tan, Y. (2024). Therapeutic progress in relapsed/refractory multiple myeloma. Annals of Hematology. https://doi.org/10.1007/s00277-024-05730-y

Vancouver

Chen Q, Zhang M, Zheng S, Tong Y, Tan Y. Therapeutic progress in relapsed/refractory multiple myeloma. Annals of Hematology. 2024. doi:10.1007/s00277-024-05730-y

BibTeX
@article{Chen2024,
  author = {Chen, Qi and Zhang, Min and Zheng, Shan and Tong, Yuxin and Tan, Yamin},
  title = {Therapeutic progress in relapsed/refractory multiple myeloma},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-05730-y}
}
Kostenlos starten →